Free Trial
NASDAQ:BYSI

BeyondSpring Q2 2026 Earnings Results & Report

BeyondSpring logo
$0.61 +0.00 (+0.21%)
As of 09:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BeyondSpring beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.02 versus the -$0.54 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

BeyondSpring EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.54
Beat/Miss
Beat by +$0.52
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

BeyondSpring Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.77 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

BeyondSpring's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

BeyondSpring Q2 2026 Earnings FAQ

BeyondSpring (NASDAQ:BYSI) reported earnings of -$0.02 per share for Q2 2026, beating the consensus estimate of -$0.54. The report was announced on Friday, August 14, 2026.

BeyondSpring's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for BeyondSpring on the company's earnings history page.

BeyondSpring Earnings Headlines

BeyondSpring Shareholders Ratify 2026 Auditor Appointment
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.tc pixel
BeyondSpring Wins FDA Fast Track for Plinabulin Lung Cancer Program
BeyondSpring Faces Nasdaq Listing Compliance Risk
See More BeyondSpring Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeyondSpring? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeyondSpring and other key companies, straight to your email.

About BeyondSpring

BeyondSpring (NASDAQ:BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research centers on treatments designed to improve outcomes for patients receiving chemotherapy and to enhance the body’s immune response against tumors.

BeyondSpring’s lead product candidate is plinabulin, also known as BPI-2358 or NPI-2358. Plinabulin is a small-molecule therapy being studied for the prevention of chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells, as well as for possible use in oncology treatment combinations. The company has also investigated plinabulin in combination with other cancer therapies and across multiple tumor types.

Founded in 2010, BeyondSpring has conducted clinical development activities in the United States and China, among other international markets. The company was led by co-founder Lan Huang, who has served as chief executive officer and chairman. BeyondSpring’s programs have progressed through clinical testing and regulatory review, although the development and approval status of individual candidates may change as the company receives additional regulatory and clinical feedback.

View BeyondSpring Profile